Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963242 | 0.85 | CYP2D6 (0.47) | CYP2D6TACR1OPRM1OPRL1SMN1; SMN2 | |
| SCHEMBL14507950 | 0.79 | SLC6A4 (0.61) | CYP2D6TACR1OPRM1OPRL1SMN1; SMN2 | |
| SCHEMBL10057690 | 0.78 | CYP2D6 (0.62) | CYP2D6TACR1OPRM1OPRL1SMN1; SMN2 | |
| SCHEMBL13923327 | 0.75 | CYP2D6 (0.67) | CYP2D6TACR1OPRM1OPRL1SMN1; SMN2 | |
| SCHEMBL6499421 | 0.72 | CYP2D6 (0.62) | CYP2D6OPRM1OPRL1SMN1; SMN2OPRD1 | |
| SCHEMBL19998533 | 0.71 | CYP2D6 (0.61) | CYP2D6TACR1OPRM1OPRL1SMN1; SMN2 | |
| SCHEMBL8353680 | 0.71 | L3MBTL1 (0.46) | CYP2D6OPRM1OPRL1OPRK1 | |
| SCHEMBL14507951 | 0.71 | CYP2D6 (0.66) | CYP2D6OPRM1OPRL1OPRK1 | |
| SCHEMBL16565591 | 0.71 | OPRM1 (0.52) | CYP2D6OPRM1SMN1; SMN2OPRD1OPRK1 | |
| SCHEMBL14507953 | 0.71 | CYP2D6 (0.60) | CYP2D6OPRM1OPRL1SMN1; SMN2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | CYP2D6 619/4885TACR1 2662/4885OPRM1 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.